It has been described that patients with the variant PAX7-FKHR translocation have a more favorable prognosis and there has been a strikingly better outcome in patients with metastatic disease and variant-trans¬location-positive alveolar RMS (estimated 4-year overall survival, 75% vs. 8% for patients with PAX3-FKHR-positive alveolar RMS) (10). The gene discussed is FOXO1; the disease is metastatic neoplasm.